UA29464C2 - Активне начало лікарського засобу, призначеного для лікування хвороби паркінсона і синдромів паркінсона та спосіб одержання вказаного лікарського засобу - Google Patents

Активне начало лікарського засобу, призначеного для лікування хвороби паркінсона і синдромів паркінсона та спосіб одержання вказаного лікарського засобу

Info

Publication number
UA29464C2
UA29464C2 UA95073383A UA95073383A UA29464C2 UA 29464 C2 UA29464 C2 UA 29464C2 UA 95073383 A UA95073383 A UA 95073383A UA 95073383 A UA95073383 A UA 95073383A UA 29464 C2 UA29464 C2 UA 29464C2
Authority
UA
Ukraine
Prior art keywords
drug
parkinson
disease
agent
preparation
Prior art date
Application number
UA95073383A
Other languages
English (en)
Russian (ru)
Inventor
Ален Буаро
Адам Добль
П'єр Дюбеда
Ерік ЛУВЕЛЬ
Ерик Лувель
Міріель Меньє
Мириель Меньє
Жан-Марі Міке
Жан-Мари МИКЕ
Жан-Марі ШТУТЦМАНН
Жан-Мари ШТУТЦМАНН
Original Assignee
Рон- Пуленк Рорер С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рон- Пуленк Рорер С.А. filed Critical Рон- Пуленк Рорер С.А.
Publication of UA29464C2 publication Critical patent/UA29464C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Винахід стосується нового терапевтичного застосування рилузолу (6-трифторметоксі-2-амінобензотіазолу) або фармацевтично придатних солей цієї сполуки. .
UA95073383A 1993-01-07 1994-01-03 Активне начало лікарського засобу, призначеного для лікування хвороби паркінсона і синдромів паркінсона та спосіб одержання вказаного лікарського засобу UA29464C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9300074A FR2700117B1 (fr) 1993-01-07 1993-01-07 Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
PCT/FR1994/000003 WO1994015601A1 (fr) 1993-01-07 1994-01-03 Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens

Publications (1)

Publication Number Publication Date
UA29464C2 true UA29464C2 (uk) 2000-11-15

Family

ID=9442862

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95073383A UA29464C2 (uk) 1993-01-07 1994-01-03 Активне начало лікарського засобу, призначеного для лікування хвороби паркінсона і синдромів паркінсона та спосіб одержання вказаного лікарського засобу

Country Status (23)

Country Link
US (2) US5674885A (uk)
EP (2) EP0678023B1 (uk)
JP (2) JPH08505379A (uk)
KR (2) KR100298807B1 (uk)
AT (2) ATE144420T1 (uk)
AU (3) AU677279B2 (uk)
CA (2) CA2153341A1 (uk)
CZ (2) CZ284363B6 (uk)
DE (2) DE69400435T2 (uk)
DK (2) DK0678026T3 (uk)
ES (2) ES2092890T3 (uk)
FR (1) FR2700117B1 (uk)
GR (2) GR3020975T3 (uk)
HU (2) HU217136B (uk)
IL (3) IL108286A0 (uk)
MX (2) MX9307885A (uk)
NO (2) NO307495B1 (uk)
PL (2) PL309596A1 (uk)
RU (1) RU2221563C2 (uk)
SK (2) SK279645B6 (uk)
UA (1) UA29464C2 (uk)
WO (3) WO1994015607A1 (uk)
ZA (3) ZA9428B (uk)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6119094A (en) * 1996-02-29 2000-09-12 Electronic Data Systems Corporation Automated system for identifying alternate low-cost travel arrangements
JP2002500181A (ja) * 1998-01-09 2002-01-08 モア−リサーチ・アプリケーシヨンズ・リミテツド ジスキネジーの処置
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6506378B1 (en) * 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
JP2004526706A (ja) * 2001-02-12 2004-09-02 テバ ファーマシューティカル インダストリーズ リミティド オクスカルバゼピンの新しい結晶形態及びそれらの調製方法
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
WO2005037276A1 (en) * 2003-10-09 2005-04-28 Aventis Pharma S.A. Use of riluzole for the treatment of essential tremor
CA2471666C (en) * 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
WO2007022568A1 (en) 2005-08-25 2007-03-01 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
EP1815849A1 (en) * 2006-01-31 2007-08-08 Teva Pharmaceutical Industries Ltd Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
ES2360423T3 (es) * 2006-04-26 2011-06-03 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal.
EP2212344B1 (en) * 2007-09-14 2014-03-26 Formycon AG Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
CN102292094B (zh) 2009-01-20 2013-08-14 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 增强神经药方疗效的山梨酸与苯甲酸及其衍生物
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
ES2936094T3 (es) 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos
RU2765625C2 (ru) 2016-06-13 2022-02-01 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
EP3638283B1 (en) * 2017-06-14 2024-07-17 Lario Therapeutics Ltd. Antagonists of cav2.3 r-type calcium channels for the treatment of neurodegenerative diseases
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
WO2021055890A1 (en) * 2019-09-20 2021-03-25 Icahn School Of Medicine At Mount Sinai Controlled release formulations of riluzole and their uses
CN113214177B (zh) * 2021-04-16 2022-05-03 上海奥科达生物医药科技有限公司 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物
WO2025063698A1 (en) * 2023-09-18 2025-03-27 Aribio Co. Ltd Lamotrigine and rivastigmine combinations for treating neurodegenerative disorders
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
FR2619713B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.

Also Published As

Publication number Publication date
IL108284A0 (en) 1994-04-12
HU217136B (hu) 1999-11-29
SK279645B6 (sk) 1999-01-11
WO1994015610A1 (fr) 1994-07-21
NO952309L (no) 1995-06-12
AU677279B2 (en) 1997-04-17
EP0678023B1 (fr) 1996-10-23
NO307495B1 (no) 2000-04-17
ES2092890T3 (es) 1996-12-01
GR3021438T3 (en) 1997-01-31
WO1994015607A1 (fr) 1994-07-21
IL108286A0 (en) 1994-04-12
IL108284A (en) 1999-03-12
FR2700117A1 (fr) 1994-07-08
NO952309D0 (no) 1995-06-12
AU5818994A (en) 1994-08-15
DE69400799D1 (de) 1996-11-28
HU9502065D0 (en) 1995-09-28
FR2700117B1 (fr) 1995-02-03
HUT72328A (en) 1996-04-29
CZ284363B6 (cs) 1998-11-11
ZA9426B (en) 1994-08-11
KR960700059A (ko) 1996-01-19
AU684059B2 (en) 1997-12-04
DE69400435T2 (de) 1997-03-06
SK86695A3 (en) 1996-05-08
JP3120153B2 (ja) 2000-12-25
PL309594A1 (en) 1995-10-30
DE69400799T2 (de) 1997-03-13
JPH08505378A (ja) 1996-06-11
US5658900A (en) 1997-08-19
HUT72074A (en) 1996-03-28
RU2221563C2 (ru) 2004-01-20
DK0678023T3 (da) 1996-11-25
WO1994015601A1 (fr) 1994-07-21
DK0678026T3 (da) 1996-09-16
SK279758B6 (sk) 1999-03-12
CZ284928B6 (cs) 1999-04-14
CA2153341A1 (fr) 1994-07-21
AU5819094A (en) 1994-08-15
ZA9428B (en) 1994-08-11
EP0678026B1 (fr) 1996-08-28
US5674885A (en) 1997-10-07
HU9502063D0 (en) 1995-09-28
JPH08505379A (ja) 1996-06-11
ES2091689T3 (es) 1996-11-01
GR3020975T3 (en) 1996-12-31
EP0678026A1 (fr) 1995-10-25
KR960700054A (ko) 1996-01-19
IL108285A0 (en) 1994-04-12
ZA9432B (en) 1994-08-11
CA2153340A1 (fr) 1994-07-21
CZ176495A3 (en) 1995-12-13
CZ176595A3 (en) 1995-12-13
SK86795A3 (en) 1995-11-08
MX9400287A (es) 1994-07-29
MX9307885A (es) 1994-07-29
AU5818894A (en) 1994-08-15
ATE144420T1 (de) 1996-11-15
EP0678023A1 (fr) 1995-10-25
NO952310D0 (no) 1995-06-12
CA2153340C (fr) 2002-12-17
KR100298807B1 (ko) 2001-11-22
ATE141792T1 (de) 1996-09-15
PL309596A1 (en) 1995-10-30
NO952310L (no) 1995-06-12
DE69400435D1 (de) 1996-10-02

Similar Documents

Publication Publication Date Title
UA29464C2 (uk) Активне начало лікарського засобу, призначеного для лікування хвороби паркінсона і синдромів паркінсона та спосіб одержання вказаного лікарського засобу
GR3022797T3 (en) Application of 2-amino 6-trifluoromethoxy benzothiazole (riluzole) for obtaining a drug useful in the treatment of motor neuron diseases.
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
PL306590A1 (en) Substituted heterocyclic carboxylamides, method obtaining them and their application as therapeutic agents
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
EP0331620A3 (en) Agent for the treatment of parkinson's disease
HUP9903906A3 (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
FR2777781B1 (fr) Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
IL134263A0 (en) Use of phanquinone for the treatment of alzheimer's disease
IL87522A0 (en) Pharmaceutical preparations for the treatment of schizophrenia comprising a benzothiazole derivative
AU3843195A (en) Use of R-(Z) -alpha-(methoxyimino)-alpha-(1-azabicyclo 2.2.2 oct-3-yl) acetonitrile to reduce amyloid beta A4 formation in Alzheimer's disease
GR3022608T3 (en) USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE.
IL106751A0 (en) Pharmaceutical compositions for the treatment of reversible obstructive airways diseases
AU1807592A (en) New combination preparation for treatment of parkinson's disease
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
CS22891A2 (en) Application of benzylphosphonic acid's derivatives for treatment of virusinduced diseases
AU1753188A (en) Treating agents for renal diseases